- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00907452
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
This protocol (in patients aged 65 and over suffering from previously untreated multiple myeloma), represents the first worldwide, pharmacogenomic study on this scale in terms of the number of patients analyzed and the implemented molecular diagnostics resources. The goal is to be able to identify patients who will best respond to the study treatments or experience the fewest associated side effects and improve prognosis, in order to optimize care management in multiple myeloma.
To this end, the study seeks to predict the following parameters in these patients:
- The treatment response and occurrence of adverse events linked to a lenalidomide-dexamethasone combination or a melphalan-prednisone-thalidomide combination.
- Progression-free survival and overall survival.
Prediction of the treatment response and the occurrence of adverse effects will be based on:
- An analysis of constitutive genetic traits linked to single nucleotide polymorphisms and DNA copy number variations.
- An analysis of changes in the tumor's genotype (change in the DNA copy number) and phenotype (altered gene and micro-RNA expression).
Prediction of progression-free survival and overall survival will be based on an analysis of changes in the tumor's genotype and phenotype.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Albi, France
- CH Albi
-
Angers, France
- CHRU Angers
-
Bayonne, France
- CH Cote Basque
-
Blois, France
- CH BLOIS
-
Bordeaux, France
- Bordeaux
-
Chalon-sur-Saône, France
- Chalon sur Saone
-
Dijon, France
- CHU Dijon
-
Dunkerque, France
- Ch Dunkerque
-
Grenoble, France
- CHU Grenoble
-
La Roche Sur Yon, France
- CHD Vendee
-
Lille, France
- CHRU Lille
-
Lyon, France
- CHU LYON
-
Lyon, France
- Lyon Sud
-
Marseille, France
- IPC Marseille
-
Metz, France
- CHR Metz
-
Mulhouse, France
- CH Mulhouse
-
Nancy, France
- Chu Nancy
-
Nantes, France
- CHU Nantes
-
Nice, France
- Centre Antoine Lacassagne
-
Paris, France
- Institut Curie
-
Poitiers, France
- CHU Poitiers
-
Rennes, France
- CHU Rennes
-
St Brieuc, France
- CH Yves Le Foll
-
St CLOUD, France
- René Huguenin
-
Toulouse, France
- CHU Toulouse
-
Tours, France
- Chu Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form
- Age ≥ 65 years at the time of signing consent
Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below: MM diagnostic criteria (all 3 required)
- Monoclonal plasma cells in the bone marrow ≥10% and/or presence of a biopsy-proven plasmacytoma
- Monoclonal protein present in the serum and/or urine
Myeloma-related organ dysfunction (at least one of the following):
- Calcium elevation in the blood (serum calcium > 10.5 mg/l or upper limit of normal)
- Renal insufficiency (serum creatinine > 2 mg/dl)
- Anemia (hemoglobin < 10 g/dl or 2 g < normal)
- Lytic bone lesions or osteoporosis
have measurable disease by protein electrophoresis analyses as defined by the following:
- IgG multiple myeloma: Serum monoclonal paraprotein (M-protein)level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 h
- IgA multiple myeloma: Serum M-protein level ³ 0.5 mg/dL or urine M-protein level³ 200 mg/24 h
- IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dL or urine Mprotein level ≥ 200 mg/24h
- IgD multiple myeloma: Serum M-protein level ≥ 0.05 g/dL or urine M-protein level ≥ 200 mg/24h
- Light chain multiple myeloma: Serum M-protein level ≥ 1.0 g/dL or urine Mprotein level ≥ 200 mg/24 hours
- ECOG performance status of 0, 1, or 2
- Treated by either melphalan-prednisone-thalidomide or lenalidomide- dexamethasone
Exclusion Criteria:
- Previous treatment with antimyeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e., less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 28 days (4 weeks) of randomization]
- Any serious medical condition that places the patient at an unacceptable risk if he or she participates in this study
Any of the following laboratory abnormalities :
- Absolute neutrophil count (ANC) < 1,000 cells/µL (1.0 x 109/L)
- Platelet count < 50,000 cells/µL (50 x 109/L) for patients in whom < 50% of bone marrow nucleated cells are plasma cells; but platelet count < 30,000/µL for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells
- Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)
- Creatinine clearance ≤ 30 mL/min (Cockroft-Gault calculation)
Prior history of malignancies, other than multiple myeloma, unless the subject has been free of the disease for ≥ 3 years. Exceptions include the following:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
- Patients who have are unable or unwilling to undergo antithrombotic therapy
- Peripheral neuropathy of > grade 2 severity
- Known HIV positivity or active infectious hepatitis, type A, B, or C.
- Primary AL amyloidosis and myeloma complicated by amyloidosis.
- Renal failure requiring dialysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: melphalan-prednisone-thalidomide
|
|
Active Comparator: lenalidomide-dexamethasone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best response to treatment
Time Frame: 1 year
|
best response rate
|
1 year
|
Collaborators and Investigators
Investigators
- Study Chair: Philippe MOREAU, Pr, Departement of clinical Hematology (University Hospital of Nantes)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Dexamethasone
- Thalidomide
- Lenalidomide
- Prednisone
- Melphalan
Other Study ID Numbers
- IFM 2007-03
- Eudract: 2008-003486-58
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
Tel-Aviv Sourasky Medical CenterCompletedPlasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Myeloma, Plasma-CellIsrael
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on melphalan-prednisone-thalidomide
-
Central Hospital, Nancy, FranceTerminated
-
Fondazione EMN Italy OnlusCompleted
-
Gruppo Italiano Studio LinfomiCompleted
-
PETHEMA FoundationCompleted
-
Grupo de Estudos Multicentricos em Onco-HematologiaUnknown
-
Fondazione EMN Italy OnlusCompleted
-
Austrian Forum Against CancerCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedMultiple MyelomaUnited States
-
European Myeloma NetworkFondazione EMN Italy OnlusCompleted
-
CelgeneCompletedMultiple MyelomaKorea, Republic of, United States, France, Belgium, Canada, Spain, United Kingdom, Australia, Italy, New Zealand, China, Portugal, Switzerland, Taiwan, Austria, Greece, Germany, Ireland, Sweden